Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation
Steven S. Tau, Mary Dickinson Chamberlin, Huijuan Yang, Jonathan D. Marotti, Patricia C. Muskus, Alyssa M. Roberts, Melissa M. Carmichael, Lauren E. Cressey, Christo Philip C. Dragnev, Eugene Demidenko, Riley A. Hampsch, Shannon M. Soucy, F. W. Kolling, Kimberley S. Samkoe, James V. Alvarez, , Todd W. Miller
This study identifies mitochondrial oxidative phosphorylation as a metabolic vulnerability in endocrine-tolerant persister ER+ breast cancer cells, suggesting therapeutic targeting of mitochondrial function could prevent recurrence.
Cancer Research · Jan 8, 2025Peer-reviewedCancer Biology